Diabetes Research and Clinical Practice
Volume 59, Issue 3 , Pages 165-180 , March 2003

The prevention of type 2 diabetes — lifestyle change or pharmacotherapy? A challenge for the 21st century

  • R.W Simpson

      Affiliations

    • Department of Diabetes and Endocrinology and Monash University Department of Medicine, Box Hill Hospital, Arnold St., Box Hill 3128, Australia
    • Corresponding Author InformationCorresponding author
    • ,
  • J.E Shaw

      Affiliations

    • International Diabetes Institute, Caulfield and Monash University, Australia
    • ,
  • P.Z Zimmet

      Affiliations

    • International Diabetes Institute, Caulfield and Monash University, Australia

Received 17 June 2002 ,Revised 9 September 2002 ,Accepted 13 November 2002.

References 

  1. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the doomsday scenario be averted?. J. Intern. Med. 2002;247:301–310
  2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. 1997;14(Suppl. 5):S1–S85
  3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414–1431
  4. Zimmet P. Diabetes epidemiology as a trigger to diabetes research and care. Diabetologia. 1999;42:499–518
  5. Dunstan DW, Zimmet PZ, Welborn TA, et al.  The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829–834
  6. Harris MI, Flegal KM, Cowie CC, et al.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–524
  7. Cockram CS, Woo J, Lau E, et al.  The prevalence of diabetes mellitus and impaired glucose tolerance among Hong Kong chinese adults of working age. Diabetes Res. Clin. Pract. 1993;21:67–73
  8. Ohmura T, Ueda K, Kiyohara Y, et al.  Prevalance of type 2 (non-insulin- dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama study. Diabetologia. 1993;36:1197–1203
  9. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M. Rising prevalence NIDDM in an urban population in India. Diabetologia. 1997;40:232–237
  10. Dowse DK, Gareeboo H, Zimmet PZ, et al.  High prevalence of NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes. 1990;39:390–396
  11. American Diabetes Association, Economic consequences of diabetes mellitus in the US in 1997, Diabetes Care 21 (1998) 296–309.
  12. Harris MI, Zimmet P. Classification of diabetes mellitus and other categories of glucose intolerance. In:  Alberti KGMM,  Zimmet P,  DeFronzo RA,  Keen H editor. International Textbook of Diabetes Mellitus. 2nd ed.. Chichester: Wiley; 1997;p. 9–23
  13. World Health Organization Consultation, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, Diabet. Med. 15 (1998) 539–53.
  14. Zimmet P, Turner RC, McCarty DJ, Rowley MJ, MacKay IR. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care. 1999;22(Suppl. 2):B59–B64
  15. Turner RC, Stratton I, Horton V, et al.  UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997;350:1288–1293
  16. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity and demography. Diabetes Care. 1995;18:1050–1064
  17. S. Serjeantson, P. Zimmet, Genetics of non-insulin dependent diabetes mellitus in 1990, in: B. Tait, L. Harrison (Eds.), Bailliere's Clin. Endocrinol. Metab., 1991, pp. 477–493.
  18. Pyke DA. Diabetes: the genetic connections. Diabetologia. 1979;17:333–343
  19. De Courten M, Bennett PH, Tuomilehto J, Zimmet P. Epidemiology of NIDDM in non-Europids. In:  Alberti KGMM,  Zimmet P,  DeFronzo RA,  Keen H editor. International Textbook of Diabetes Mellitus. 2nd ed.. Chichester: Wiley; 1997;p. 143–170
  20. Hattersley AT. Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet. Med. 1998;15:15–24
  21. McIntyre EA, Walker M. Genetics of type 2 diabetes and insulin resistance: knowledge from human studies. Clin. Endocrin. 2002;57:303–311
  22. Bennett PH, Bogardus C, Tuomilehto J, Zimmet P. Epidemiology and natural history of NIDDM: non-obese and obese. In:  Alberti KGMM,  DeFronzo RA,  Keen H,  Zimmet P editor. International Textbook of Diabetes Mellitus. 1st ed.. Chichester: Wiley; 1992;p. 147–176
  23. Dowse GK, Gareeboo H, Zimmet P, et al.  High prevalence of NIDDM and impaired glucose tolerance in Indian, Creole and Chinese Mauritians. Mauritius Non-communicable Disease Study Group. Diabetes. 1990;39:390–396
  24. Cohen MP, Stern E, Rusecki Y, Zeidler A. High prevalence of diabetes in young adult Ethiopian immigrants to Israel. Diabetes. 1988;37:824–828
  25. World Health Organization, Diabetes Mellitus: Report of a WHO Study Group, WHO, Geneva, 1985.
  26. Tuomilehto J, Knowler W, Zimmet P. Primary prevention of non-insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 1992;8:339–353
  27. Alberti KGMM. The clinical implications of impaired glucose tolerance. Diabet. Med. 1996;13:927–937
  28. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes. J. Am. Med. Assoc. 1990;263:2893–2898
  29. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin dependent diabetes in a community of older adults. Am. J. Epidemiol. 1990;131:443–453
  30. Saad MF, Knowler WC, Pettitt DJ, Welson RG, Charles MA, Bennett PH. A two step model for development of non-insulin-dependant diabetes. Am. J. Med. 1991;90:229–235
  31. Hamman RF. Genetics and environmental determinants of non-insulin-dependant-diabetes-mellitus (NIDDM). Diabetes Metab. Rev. 1992;8:287–338
  32. Yudkin JS, Alberti KGMM, McLarty DG, Swai ABN. Impaired glucose tolerance. Br. Med. J. 1990;301:397–401
  33. Swai ABM, Harrison K, Chuwa LM, Makene W, McLarty DG, Alberti KGMM. Screening for diabetes. Does measurement of frustosamine help?. Diabet. Med. 1988;5:648–652
  34. Albutt EC, Nattrass M, Northam BE. Glucose tolerance test and glycoslylated haemoglobin measurement for diagnosis of diabetes mellitus-an assessment of the criteria of the WHO Expert Committee on Diabetes Mellitus. Ann. Clin. Biochem. 1985;22:67–73
  35. The DECODE study group on behalf of the European epidemiology group. Glucose tolerance and mortality; comparison of WHO and American Diabetes Association diagnostic criteria, Lancet 354 (1994) 617–21.
  36. Dowse GK. Incidence of NIDDM and the natural history of IGT in Pacific and Indian Ocean populations. Diabetes Res. Clin. Pract. 1996;34(Suppl. 1):S45–S50
  37. Edelstein SL, Knowler WC, Bain RP, et al.  Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–710
  38. Tuomilehto J, Tuomilehto-Wolf E, Zimmet P, Alberti KGMM, Knowler WC. Primary prevention of diabetes mellitus. In:  Alberti KGMM,  Zimmet P,  DeFronzo RA,  Keen H editor. International Textbook of Diabetes Mellitus. 2nd ed.. Chichester: Wiley; 1997;p. 1799–1827
  39. Zimmet P. Kelly West Lecture. Challenges in diabetes epidemiology — from West to the rest. Diabetes Care. 1991;15(1992):232–252
  40. Hodge AM, de Courten MP, Zimmet P. Obesity and type 2 diabetes mellitus. In:  Bjorntorp P editors. International Textbook of Obesity. Chichester: Wiley; 2001;p. 351–364
  41. Manson JE, Spelsberg A. Primary prevention of non-insulin-dependent diabetes mellitus. Am. J. Prev. Med. 1994;10:172–184
  42. Westlund K, Nicolaysen R. Ten-year mortality and morbidity related to serum cholesterol. A follow-up of 3751 men aged 40–49. Scand. J. Clin. Invest. 1972;30(Suppl. 127):1–24
  43. Medalie JH, Papier CM, Herman JB, et al.  Diabetes mellitus among 10,000 adult men: 5-year incidence and associated variables. Isr. J. Med. Sci. 1974;10:681–697
  44. Ohlson LO, Larsson B, Bjorntorp P, et al.  The risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and half years of follow-up of the participants in the study of men born in 1913. Diabetologia. 1988;31:798–805
  45. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 1995;122:481–486
  46. Björntorp P. Visceral obesity: a ‘Civilization Syndrome’. Obesity Res. 1993;1:206–222
  47. Marshall JA, Hamman RF, Baxter J. High fat, low carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus. San Luis Valley Diabetes Study. Am. J. Epidemiol. 1991;134:590–603
  48. Marshall JA, Hoag S, Shetterley S, Hamman RF. Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. Diabetes Care. 1994;17:50–56
  49. Hu FB, Van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia. 2001;44:805–817
  50. Salmeron J, Hu FB, Manson JE. Dietary fat intake and risk of type 2 diabetes in women. Am. J. Clin. Nutr. 2001;73:1019–1027
  51. Salmeron J, Ascherio A, Rimm EB, et al.  Dietary fibre, glycemic load and risk of NIDDM in men. Diabetes Care. 1997;20:545–550
  52. Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willet WC. Dietary fibre, glycemic load and risk of non-insulin-dependent diabetes in women. J. Am. Med. Assoc. 1997;277:472–477
  53. Meyer KA, Kushi LH, Jacobs DR, Slavin J, Sellers TA, Folsom AR. Carbohydrates, dietary fibre and incidence of type 2diabetes in older women. Am. J. Clin. Nutr. 2000;71:921–930
  54. Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. Br. Med. J. 1995;310:560–564
  55. Ajani UA, Hennekens CH, Spelsberg A, Manson JE. Alcohol consumption and risk of type 2 diabetes mellitus among US male physicians. Arch. Intern. Med. 2000;160:1025–1030
  56. Kriska A, Bennett PH. An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. Diabetes Metab. Rev. 1992;8:355–372
  57. Ballor DL, Keesey RE. A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass and fat-free mass in males and females. Int. J. Obes. 1991;15:717–726
  58. Ross R, Dagnone D, Jones PJ, et al.  Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann. Intern. Med. 2000;133:92–103
  59. Mayer-Davis E, D'Agostino RJ, Karter A, et al.  Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. J. Am. Med. Assoc. 1998;279:669–674
  60. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth?. Br. Med. J. 1995;311:437–439
  61. Long SD, O'Brien K, McDonald KG, et al.  Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type 2 diabetes. A longitudinal interventional study. Diabetes Care. 1994;17:372–375
  62. Himsworth HB. Diet and the incidence of diabetes mellitus. Clin. Sci. 1935;2:1148–1177
  63. Mann JI, Hueston A. Aetiology of Non Insulin Dependent Diabetes. In:  Mann JI,  Pyorala K,  Teuscher A editor. Diabetes in Epidemiological Perspective. 1st ed.. Edinburgh: Churchill Livingstone; 1983;p. 122–164
  64. Westlund K. Incidence of diabetes mellitus in Oslo, Norway 1925 to 1954. Br. J. Prev. Soc. Med. 1966;20:105–116
  65. Sartor G, Schersten B, Carlström S, Melander A, Norden A, Persson G. Ten year follow up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29:41–49
  66. Ramaiya KL, Swai ABM, Alberti KGMM, McLarty DG. Lifestyle changes, decreased rates of glucose intolerance and cardiovascular (CVD) risk factors. Diabetologia. 1992;35(Suppl. 1):A60
  67. Bourn DM, Mann JI, McSkimming BJ, Waldron MA, Wishart JD. Impaired glucose tolerance and NIDDM: does a lifestyle intervention program have an effect?. Diabetes Care. 1994;17:1311–1319
  68. Lynch J, Helmich SP, Lakka TA, et al.  Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle aged men. Arch. Intern. Med. 1996;156:1307–1314
  69. Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I, Holme I, Urdal P. Lifestyle changes may reverse development of the insulin resistant syndrome. The Oslo Diet and Exercise Study: a randomised trial. Diabetes Care. 1997;20:26–31
  70. O'Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle. Diabetes Care. 1984;33:596–603
  71. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991;34:891–898
  72. Pan XR, Li GW, Hu YH, et al.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544
  73. Tuomilehto J, Lindstrom J, Eriksson JG, et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344:1343–1350
  74. The Diabetes Prevention Program, Design and methods for a clinical trial in the prevention of type 2 diabetes, Diabetes Care 22 (1999) 623–34.
  75. Knowler WC, Barrett-Conner E, Fowler SE, et al.  Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393–403
  76. Hammersley MS, Meyer LC, Morris RJ, Manley SE, Turner RC, Holman RR. The Fasting Hyperglycemia Study. 1 Subjects, identification and recruitment for a non-insulin dependent diabetes prevention trial. Metabolism. 1997;46(Suppl. 1):44–49
  77. P.A. Dyson, M.S. Hammersley, R.J. Morris, R.R. Holman, R.C. Turner, The Fasting Hyperglycemia Study. II Randomised controlled trial of reinforced healthy living advice in subjects with increased but not diabetic fasting plasma glucose, Metabolism 46 (Suppl. 1) (1997) 50–5.
  78. The Writing Group for the Activity Counseling Trial Research Group. Effects of physical activity counseling in primary care. The Activity Counseling Trial: a randomized controlled trial, J. Am. Med. Assoc. 286 (2001) 677–87.
  79. Swinburne BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care. 2001;24:619–624
  80. Fajans SS, Cohn JW. Tolbutamide-induced improvement in carbohydrate tolerance in young people with mild diabetes mellitus. Diabetes. 1960;9:83–88
  81. Engelhardt HT, Veccio TJ. The long term effect of tolbutamide on glucose tolerance in adults. asymptomatic latent diabetes. Metabolism. 1965;14:885–890
  82. Belknap BH, Bagdade JD, Amaral JAP, Bierman EL. Plasma lipids and mild glucose intolerance. II A double blind study of the effect of tolbutamide and placebo in mild adult diabetic outpatients. Excepta Med. Int. Congr. Serv. 1967;149:171–176
  83. Paasikivi J, Wahlberg F. Preventative tolbutamide treatment and arterial disease on mild hyperglycaemia. Diabetologia. 1971;7:323–327
  84. Camerini-Davalosra RA. Treatment of chemical diabetes. Excepta Med. Int. Congr. Serv. 1967;149:228–242
  85. Keen H, Jarrett RJ, McCartney P. The 10-year follow-up of the Bedford Survey: glucose tolerance and diabetes. Diabetologia. 1962;22(1982):73–78
  86. Jarrett RJ, Keen H, Fuller JH, McCartney M. Treatment of borderline diabetes: controlled trial using carbohydrate restriction and phenformin. Br. Med. J. 1977;2:861–865
  87. Papoz L, Job D, Eschwege E, et al.  The effect of oral hypoglycemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients. Diabetologia. 1978;15:373–380
  88. Ratzmann KP, Witt S, Schulz B. The effect of long term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance. Diabet. Metab. 1983;9:87–93
  89. Cederholm J. Short term treatment of glucose intolerance in middle-aged subjects by diet, exercise and sulphonylurea. Ups. J. Med. Sci. 1985;90:229–242
  90. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. for The STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus; the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077
  91. Buchanann TA, Xiang AH, Peters RK, et al.  Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803
  92. Wenying Y, Lixiang L, Jinwu Q, et al.  The preventative effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicentre prospective study. Chin. J. Endocrinol. Metab. 2001;17:131–135
  93. Holman RR, North BV, Tunbridge FK. Possible prevention of type 2 diabetes with acarbose or metformin. Diabetes. 2000;49(Suppl. 1):450P
  94. Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR. The fasting Hyperglycaemia Study. III. Randomised controlled trial of sulphonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism. 1997;46(Suppl. 1):56–60
  95. Hansson L, Lindholm LH, Niskanen L, et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captropril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616
  96. Gress TW, Nieto FJ, Sharhar E, Wofford MR, Brancati FL. Hypertension and anti-hypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 2000;342:905–912
  97. Yusuf S, Gerstein H, Hoogwerf B, et al.  for the HOPE study investigators. Ramipril and the development of diabetes. J. Am. Med. Assoc. 2001;286:1882–1885
  98. Hansson L, Lindholm LH, Ekbom T, et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–1756
  99. Dahlof B, Devereux RB, Kjeldsen SE, et al.  for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenalol. Lancet. 2002;359:995–1003
  100. Freeman DJ, Norrie J, Sattar N, et al.  Pravastatin and the development of diabetes mellitus; evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357–362
  101. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 1998;273:3547–3550
  102. Finegood DT, McArthur MD, Buckingham RE, Leonard T. Rosiglitazone reduces net loss of pancreatic beta cell mass in Zucker Diabetic Fatty Rats. Diabetologia. 2000;43(Suppl.1):A125
  103. Prigeon RL, Kahn SE, Porte D. Effect of Troglitazone on B cell function, insulin sensitivity and glycemic control in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 1998;83:819–823
  104. Porter LE, Freed MI, Jones NP, Biswas N. Rosiglitazone reduces proinsulin/insulin ratio and improves beta cell function in type 2 diabetes. Diabetologia. 2000;43(Suppl. 1):A192
  105. Cavaghan MK, Ehrmann DA, Byrne MM, Shneider DJ, Polansky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J. Clin. Invest. 1997;100:530–537
  106. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes. 1996;44:1661–1669
  107. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycemic agents: frequency, possible causes and management. Diabetes Metab. Rev. 1994;10:31–43
  108. Hoffman CA, Edwards CW, Hillman RM, et al.  Treatment of insulin-resistant mice with the oral anti-diabetic agent pioglitazone; evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology. 1992;130:735–740
  109. Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN. Insulin action enhancement normalises brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J. Vasc. Surg. 1998;28:1024–1031
  110. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid; a long-recognised but under appreciated pathological feature of type 2 diabetes. Diabetes. 1999;48:241–253
  111. Bell PM, Hadden DR. Metformin. Endocrinol. Metab. Clin. N. Am. 1997;26:523–537
  112. Montanari G, Bondioli A, Rizzato G, et al.  Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol. Res. 1992;25:63–73
  113. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab. 2001;84:4666–4673
  114. Chaisson J-L, Josse RG, Leiter LA, et al.  The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996;19:1191–1194
  115. Chaisson J-L, Josse RG, Gomis R, et al.  Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: the STOP-NIDDM trial. Diabetologia. 2002;45(Suppl. 2A):104
  116. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycemia; the Whitehall Study. Br. Med. J. 1983;287:867–870
  117. Khaw KT, Wareham N, Luben R, et al.  Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br. Med. J. 2001;322:15–18
  118. Antonucci T, Whitcomb R, McLain R, Lockwood D, Morris RM. Impaired glucose tolerance is normalised by treatment with the thiazolidiedione troglitazone. Diabetes Care. 1997;20:188–193
  119. Dabelea D, Pettitt DJ, Jones KL, Arslanian SA. Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol. Metab. Clin. N. Am. 1999;28:709–729
  120. Hu FB, Manson JE, Stampfer MJ, et al.  Diet, lifestyle and the risk of type 2 diabetes mellitus in women. N. Engl. J. Med. 2001;345:790–797
  121. Simmons D, Voyle J, Swinburn B, O'Dea K. Community-based approaches for the primary prevention of non-insulin-dependent diabetes mellitus. Diabet. Med. 1997;14:519–526
  122. Vegt F, Dekker JM, Jager A, et al.  Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn study. J. Am. Med. Assoc. 2001;286:2109–2113
  123. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: The Hoorn study. Diabetologia. 1996;39:113–118
  124. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population. Paris Prospective Study. Diabetes. 1991;40:796–799
  125. Motala AA, Omar MA, Gouws E. High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance. Diabetes. 1993;42:556–563
  126. Shaw JE, Zimmet PZ, de Courten M, et al.  Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes?. Diabetes Care. 1999;22:399–402

☆ R.W.S. is a Principal Investigator for the DREAM and NAVIGATOR studies at Box Hill Hospital, P.Z. is a Principal Investigator for both studies and also member of steering committee for DREAM.

PII: S0168-8227(02)00275-9

Diabetes Research and Clinical Practice
Volume 59, Issue 3 , Pages 165-180 , March 2003

Article Tools

* Image Usage & Resolution